Navigation Links
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Date:10/5/2010

largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer-related bone diseases.

Over 11,000 patients have been enrolled in the denosumab oncology clinical trials, testing the drug for the reduction of SREs in patients with breast and prostate cancer, as well as other solid tumors and multiple myeloma, for the amelioration of treatment-induced bone loss in patients with non-metastatic breast or prostate cancers, and for its potential to delay bone metastases in prostate and breast cancer.

Overall rates of adverse events and serious adverse events, including infections, were generally similar between the two arms. Osteonecrosis of the jaw was infrequent (52 patients receiving denosumab as compared with 37 patients receiving Zometa) and there was no statistically significant difference between treatment arms. As with previous studies in advanced cancer patients, hypocalcemia was more frequent in the denosumab arm. Both overall survival and the time to cancer progression were balanced.About VectibixVectibix is the first fully human anti-EGFR antibody approved by the United States (U.S.) Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of mCRC trials have not shown a t
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... in the 2014 Morgan Stanley Global Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Peptide Cancer Therapeutics Market & Pipeline Insight ... The conventional methods developed to prevent and eradicate the ... treatment. These methods are confined to low specificity, safety ... researchers to look for a better solution. It has ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... Sept. 23, 2011 A pharmaceutical company,s marketing strategy ... introducing a new brand in a space where the ... two-thirds of companies, the most frequent changes require shifting ... activities, such as professional relations, promotional literature, sampling, and ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its third quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... November 1, 2011 to discuss its financial results and provide ...
Cached Medicine Technology:Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication 2Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2
(Date:8/30/2014)... Jake W., 18, is completing his high ... Back2Basics Outdoor Adventures transition program known as Beyond the ... I can actually start on a real career path,” said ... done.” , He has six months of sobriety under his ... choose to continue on to the Beyond the Basics transition ...
(Date:8/30/2014)... 2014 “In 2013, a vehicle crash occurred ... says in a recently released article on 2013 Washington ... in an auto accident every 12 minutes, and a motorcyclist ... “Based on the 2013 statistics, between now and this same ... The threat of an auto accident is real and impending ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 Zensah®, the ... Camo Compression Leg Sleeve . The camo sleeves are ... Leg Sleeve collection. The camo line includes classic colors ... and magenta. , Known as tibial stress syndrome, shin ... of the lower leg. Swollen and irritated muscles, stress fractures, ...
(Date:8/30/2014)... Barton Associates, an industry leading physician, ... , announces a new office location in Keene, NH, ... headquartered in Peabody, MA, with additional staffing centers in ... Jupiter, FL. , Barton Associates made the decision to ... crisis affecting the United States, a crisis that will ...
(Date:8/30/2014)... August 30, 2014 What challenges exist ... are the latest trends, concerns, and considerations? Sports ... Ken Pendleton recently spoke with Woody Wommack, Southeast Football ... current issues in football recruiting. Notably, Wommack spoke ... athletes, changes that he thinks are coming as a ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Now Available on Online Community to Facilitate Collaboration ... BEACH, Fla., May 8 With a growing ... short weeks since launch, e-Zassi.com has added an ... participants involved in the discovery, development and commercialization ...
... York City Raises Money for STAR (TM) ... Charcot-Marie-Tooth Association,s second annual "Honor a Star. Be a Star." ... achievement raised a record amount of over $350,000 at the ... Proceeds earned from event sponsorship, ticket sales and auction items ...
... One Global Health Threat"WASHINGTON, May 8 Today, HIV ... of Human Virology at the University of Maryland ... of the World Foundation for AIDS Research and Prevention, ... six objectives to end the HIV/AIDS pandemic. They ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide announced today it filed with the,Securities ... 20-F that included,audited financial statements for the year ... Annual Report on Form 20-F is available online,at ...
... part of the Elekta Group, has been selected to ... the 2009 American Society of Clinical Oncology,s (ASCO) Annual ... County Convention Center, in Orlando, Florida. Chosen according to ... third consecutive year Impac Software ...
... May 8, 2009 AMERIGROUP Corporation (NYSE: ... the Deutsche Bank 34th Annual Healthcare Conference on May 18 ... Monday, May 18 at 2:25pm Eastern Time, can be accessed ... the investors, page. A replay will be available for 30 ...
Cached Medicine News:Health News:New Advanced Search and Matching Function Drives e-Zassi.com's Enhanced Functionality 2Health News:Charcot-Marie-Tooth Association's 'Honor a Star. Be a Star.' Gala Generates Over $350,000 for CMT Research 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 3Health News:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Health News:Impac Software Selected to Present at the Electronic Health Records Lab During 2009 ASCO Annual Meeting 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: